BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 3152918)

  • 61. Immunological and pharmacological removal of small cell lung cancer cells from bone marrow autografts.
    Humblet Y; Feyens AM; Sekhavat M; Agaliotis D; Canon JL; Symann ML
    Cancer Res; 1989 Sep; 49(18):5058-61. PubMed ID: 2548708
    [TBL] [Abstract][Full Text] [Related]  

  • 62. In vitro sensitivity of human hematopoietic progenitor cells to 4-hydroperoxycyclophosphamide.
    Ratajczak MZ; Ratajczak J; Kuczynski W; Light B; Lusk EJ; Gewirtz AM
    Exp Hematol; 1993 Dec; 21(13):1663-7. PubMed ID: 8243568
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Density gradient separation of hematopoietic stem cells in autologous bone marrow transplantation.
    Iacone A; Quaglietta AM; D'Antonio D; Accorsi P; Dragani A; Angrilli F; Berardi A; Angelini A; Di Bartolomeo P; Di Bartolomeo G
    Haematologica; 1991 Mar; 76 Suppl 1():18-21. PubMed ID: 1677910
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Long-term engraftment failure after marrow ablation and autologous hematopoietic reconstitution: differences between peripheral blood stem cell and bone marrow recipients.
    Bentley SA; Brecher ME; Powell E; Serody JS; Wiley JM; Shea TC
    Bone Marrow Transplant; 1997 Mar; 19(6):557-63. PubMed ID: 9085735
    [TBL] [Abstract][Full Text] [Related]  

  • 65. A simple method to detect immature hemopoietic progenitors after in vitro treatment with ASTA-Z 7654.
    Lamana M; Gonzalez R; Camara R; Steegmann JL; Fernandez-Rañada JM
    Prog Clin Biol Res; 1992; 377():35-9. PubMed ID: 1438430
    [No Abstract]   [Full Text] [Related]  

  • 66. Engraftment of leukocyte subsets following autologous bone marrow transplantation in acute myeloid leukemia using anti-myeloid (CD14 and CD15) monoclonal antibody-purged bone marrow.
    Ericson SG; Colby E; Welch L; Ball ED
    Bone Marrow Transplant; 1992 Feb; 9(2):129-37. PubMed ID: 1373982
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Autologous transplantation of chemotherapy-purged PBSC collections from high-risk leukemia patients: a pilot study.
    Lemoli RM; Visani G; Leopardi G; Motta MR; Rizzi S; Testoni N; Curti A; Tura S
    Bone Marrow Transplant; 1999 Feb; 23(3):235-41. PubMed ID: 10084254
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Standardization and characterization of the procedure for in vitro treatment of human bone marrow with cyclophosphamide derivatives.
    Lopez M; Du Puymontbrun MC; Douay L; Laporte JP; Gorin NC
    Clin Lab Haematol; 1985; 7(4):327-34. PubMed ID: 3913559
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Pharmacologic bone marrow purging: is there any place for etoposide? In vitro comparison with mafosfamide.
    Olivieri A; Poloni A; Montanari M; Cantori I; Corvatta L; Masia MC; Curzi L; Mancini S; Leoni P
    J Hematother; 1997 Apr; 6(2):137-44. PubMed ID: 9131443
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Rapid engraftment after autologous transplantation utilizing marrow and recombinant granulocyte colony-stimulating factor-mobilized peripheral blood stem cells in patients with acute myelogenous leukemia.
    Demirer T; Buckner CD; Appelbaum FR; Petersen FB; Rowley S; Weaver CH; Lilleby K; Sanders J; Chauncey T; Storb R
    Bone Marrow Transplant; 1995 Jun; 15(6):915-22. PubMed ID: 7581091
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Progenitor cells purging: negative selection.
    De Rosa L; Montuoro A; Pandolfi A; Paladini U; Lanti T; Morara R; De Laurenzi A
    Int J Artif Organs; 1993 Dec; 16 Suppl 5():102-7. PubMed ID: 8013965
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Autologous blood stem cell (ABSCT) versus purged bone marrow transplantation (pABMT) in standard risk AML: influence of source and cell composition of the autograft on hemopoietic reconstitution and disease-free survival.
    Körbling M; Fliedner TM; Holle R; Magrin S; Baumann M; Holdermann E; Eberhardt K
    Bone Marrow Transplant; 1991 May; 7(5):343-9. PubMed ID: 1676924
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Interleukin-3 followed by GM-CSF for delayed engraftment after autologous bone marrow transplantation.
    Crump M; Couture F; Kovacs M; Saragosa R; McCrae J; Brandwein J; Huebsch L; Beauregard-Zollinger L; Keating A
    Exp Hematol; 1993 Mar; 21(3):405-410. PubMed ID: 8440338
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Peripheral blood stem cells as a source for hemopoietic recovery following autologous bone marrow transplantation in childhood malignancy.
    Yaniv I; Goshen J; Stein J; Ben-Zvi N; Grunspan A; Kodman Y; Luria D; Sverdlov Y; Cohen IJ; Zaizov R
    Isr J Med Sci; 1994 Aug; 30(8):634-9. PubMed ID: 8045748
    [TBL] [Abstract][Full Text] [Related]  

  • 75. [Treatment of stage IV neuroblastoma with high-dose melphalan and autologous bone marrow transplantation following in vitro preliminary treatment of the bone marrow with the active cyclophosphamide derivative Asta Z-7654].
    Urban C; Slace I; Kaulfersch W; Greinix H; Höcker P
    Padiatr Padol; 1986; 21(3):275-82. PubMed ID: 3534689
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Autologous marrow transplantation in first remission acute myeloid leukemia using marrow purged with mafosfamide.
    Rizzoli V; Mangoni L; Carlo-Stella C; Carella AM; Coser P; Angrilli F; Porcellini A; Bernabei PA
    Bone Marrow Transplant; 1991; 7 Suppl 2():37. PubMed ID: 1878710
    [No Abstract]   [Full Text] [Related]  

  • 77. New strategies in marrow purging for breast cancer patients receiving high-dose chemotherapy with autologous bone marrow transplantation.
    Shpall EJ; Stemmer SM; Bearman SI; Myers S; Purdy M; Jones RB
    Breast Cancer Res Treat; 1993; 26 Suppl():S19-23. PubMed ID: 7691269
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Protection of bone marrow stromal cells from the toxic effects of cyclophosphamide in vivo and of ASTA-Z 7557 and etoposide in vitro by ammonium trichloro(dioxyethylene-O-O')tellurate (AS101).
    Kalechman Y; Sotnik-Barkai I; Albeck M; Sredni B
    Cancer Res; 1993 Apr; 53(8):1838-44. PubMed ID: 8467503
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Use of granulocyte-macrophage colony-stimulating factor (GM-CSF) in combination with hydroxyurea as post-transplant therapy in chronic myelogenous leukemia patients autografted with unmanipulated hematopoietic cells.
    Carlo-Stella C; Regazzi E; Andrizzi C; Savoldo B; Garau D; Montefusco E; Vignetti M; Mandelli F; Rizzoli V; Meloni G
    Haematologica; 1997; 82(3):291-6. PubMed ID: 9234574
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Failure of bone marrow cryopreservation in chronic granulocytic leukemia: relation to excessive granulo-macrophagic progenitor pool.
    Douay L; Lopez M; Gorin NC; Nauman A; Giarratana MC; Laporte JP; Stachowiak J; Salmon C; Duhamel G
    Int J Cell Cloning; 1986 Jul; 4(4):250-62. PubMed ID: 2875118
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.